Norinchukin Bank The lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 182,827 shares of the biopharmaceutical company’s stock after acquiring an additional 8,427 shares during the quarter. Norinchukin Bank The’s holdings in Gilead Sciences were worth $12,940,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of GILD. Pioneer Investment Management Inc. increased its stake in shares of Gilead Sciences by 84.0% during the second quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock worth $247,245,000 after acquiring an additional 1,595,085 shares during the period. Neuberger Berman Group LLC increased its stake in shares of Gilead Sciences by 90.9% during the second quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock worth $182,839,000 after acquiring an additional 1,229,916 shares during the period. Harbour Capital Advisors LLC increased its stake in shares of Gilead Sciences by 6,595.9% during the second quarter. Harbour Capital Advisors LLC now owns 1,221,804 shares of the biopharmaceutical company’s stock worth $17,262,000 after acquiring an additional 1,203,557 shares during the period. Principal Financial Group Inc. increased its stake in shares of Gilead Sciences by 41.2% during the second quarter. Principal Financial Group Inc. now owns 3,909,105 shares of the biopharmaceutical company’s stock worth $276,687,000 after acquiring an additional 1,140,112 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Gilead Sciences by 75.0% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock worth $173,148,000 after acquiring an additional 1,092,206 shares during the period. Institutional investors and hedge funds own 76.30% of the company’s stock.

WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/21/gilead-sciences-inc-gild-stake-lifted-by-norinchukin-bank-the.html.

Gilead Sciences, Inc. (GILD) opened at $72.13 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The company has a market cap of $93,860.00, a price-to-earnings ratio of 7.56, a price-to-earnings-growth ratio of -1.21 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the prior year, the firm posted $2.75 EPS. The firm’s revenue was down 13.2% compared to the same quarter last year. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.88%. Gilead Sciences’s payout ratio is currently 23.66%.

GILD has been the topic of several recent analyst reports. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Thursday, August 31st. Deutsche Bank AG restated a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research report on Thursday, August 31st. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price on the stock in a research report on Friday, October 13th. Credit Suisse Group restated an “outperform” rating and set a $85.00 target price (up from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $84.87.

In related news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 666,819 shares of company stock worth $52,303,086. Insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.